Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Get an introduction to all features of this page

Formycon AG Stock

Price
Target price
€26.35

€26.35

0.000%
-
0.000%
€100.00
 
20.06.25 / Tradegate WKN: A1EWVY / Name: Formycon / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15JS chart by amCharts
Select a timeframe to show chart data
From: to:
Zoom:
Loading data...
Your prediction
Pros and Cons of Formycon AG in the next few years
Wizard

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Formycon AG is only available for our menbers.
Not a member yet? Sign up for free!

Financial data and news for Formycon

sharewise wants to provide you with the best news and tools for Formycon, so we directly link to the best financial data sources.

Financials

News

Broker

 

News

Formycon Stock: Biotech Firm Launches First Corporate Bond
Formycon Stock: Biotech Firm Launches First Corporate Bond

Formycon, the Munich-based biotech company, is breaking new ground in its financing strategy by issuing its first corporate bond to raise up to €50 million. The four-year unsecured bond, scheduled

StockWorldEnglish 
0 17.06.25
EQS-News: Formycon bond 2025/2029: Public subscription now also possible via Deutsche Börse
EQS-News: Formycon bond 2025/2029: Public subscription now also possible via Deutsche Börse
EQS-News: Formycon bond 2025/2029: Public subscription now also possible via Deutsche Börse
eqs_en 
0 20.06.25
EQS-News: Ordinary Annual General Meeting of Formycon AG approves all proposed resolutions by large majorities
EQS-News: Ordinary Annual General Meeting of Formycon AG approves all proposed resolutions by large majorities
EQS-News: Ordinary Annual General Meeting of Formycon AG approves all proposed resolutions by large majorities
eqs_en 
0 18.06.25
EQS-News: Formycon AG: Subscription period for 2025/2029 corporate bond has started
EQS-News: Formycon AG: Subscription period for 2025/2029 corporate bond has started
EQS-News: Formycon AG: Subscription period for 2025/2029 corporate bond has started
eqs_en 
0 18.06.25
EQS-News: Formycon plans public corporate bond issuance to support next growth phase within attractive Biosimilar markets
EQS-News: Formycon plans public corporate bond issuance to support next growth phase within attractive Biosimilar markets
EQS-News: Formycon plans public corporate bond issuance to support next growth phase within attractive Biosimilar markets
eqs_en 
0 17.06.25
EQS-Adhoc: Formycon plans to issue a public senior unsecured floating rate bond with target volume of EUR 50 million to support further company growth
EQS-Adhoc: Formycon plans to issue a public senior unsecured floating rate bond with target volume of EUR 50 million to support further company growth
EQS-Adhoc: Formycon plans to issue a public senior unsecured floating rate bond with target volume of EUR 50 million to support further company growth
eqs_en 
0 17.06.25
EQS-News: Lucentis® biosimilar FYB201/Ranivisio® (ranibizumab) approved in Brazil
EQS-News: Lucentis® biosimilar FYB201/Ranivisio® (ranibizumab) approved in Brazil
EQS-News: Lucentis® biosimilar FYB201/Ranivisio® (ranibizumab) approved in Brazil
eqs_en 
0 05.06.25
EQS-News: Formycon and Fresenius Kabi announce the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar in Canada
EQS-News: Formycon and Fresenius Kabi announce the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar in Canada
EQS-News: Formycon and Fresenius Kabi announce the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar in Canada
eqs_en 
0 27.05.25
EQS-News: Formycon and Fresenius Kabi announce FDA Approval of Interchangeability for FYB202/Otulfi® (ustekinumab-aauz)
EQS-News: Formycon and Fresenius Kabi announce FDA Approval of Interchangeability for FYB202/Otulfi® (ustekinumab-aauz)
EQS-News: Formycon and Fresenius Kabi announce FDA Approval of Interchangeability for FYB202/Otulfi® (ustekinumab-aauz)
eqs_en 
0 19.05.25
EQS-News: Formycon reports strong operational performance and financial results for first quarter of 2025
EQS-News: Formycon reports strong operational performance and financial results for first quarter of 2025
EQS-News: Formycon reports strong operational performance and financial results for first quarter of 2025
eqs_en 
0 12.05.25
EQS-News: Formycon invites to conference call on the results of the first quarter of 2025 and announces participation in international investor conferences
EQS-News: Formycon invites to conference call on the results of the first quarter of 2025 and announces participation in international investor conferences
EQS-News: Formycon invites to conference call on the results of the first quarter of 2025 and announces participation in international investor conferences
eqs_en 
0 07.05.25
EQS-News: Formycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position
EQS-News: Formycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position
EQS-News: Formycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position
eqs_en 
0 27.03.25
EQS-News: Formycon invites to conference call on the results of the financial year 2024 and announces participation in international investor conferences in the 2nd quarter of 2025
EQS-News: Formycon invites to conference call on the results of the financial year 2024 and announces participation in international investor conferences in the 2nd quarter of 2025
EQS-News: Formycon invites to conference call on the results of the financial year 2024 and announces participation in international investor conferences in the 2nd quarter of 2025
eqs_en 
0 24.03.25
EQS-News: FYB202/Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union
EQS-News: FYB202/Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union
EQS-News: FYB202/Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union
eqs_en 
0 03.03.25
EQS-News: Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
EQS-News: Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
EQS-News: Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
eqs_en 
0 25.02.25
EQS-News: Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin
EQS-News: Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin
EQS-News: Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin
eqs_en 
0 20.02.25
EQS-News: Formycon AG informs about recent developments in various biosimilar projects and invites to conference call
EQS-News: Formycon AG informs about recent developments in various biosimilar projects and invites to conference call
EQS-News: Formycon AG informs about recent developments in various biosimilar projects and invites to conference call
eqs_en 
0 17.02.25
EQS-Adhoc: Formycon announces decision on Phase III trial with FYB206 and provides update on potential need to adjust the valuation of FYB202 and FYB201
EQS-Adhoc: Formycon announces decision on Phase III trial with FYB206 and provides update on potential need to adjust the valuation of FYB202 and FYB201
EQS-Adhoc: Formycon announces decision on Phase III trial with FYB206 and provides update on potential need to adjust the valuation of FYB202 and FYB201
eqs_en 
0 17.02.25
EQS-News: Lotus Pharmaceutical becomes strategic partner for the commercialization of Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® in the Asia-Pacific Region
EQS-News: Lotus Pharmaceutical becomes strategic partner for the commercialization of Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® in the Asia-Pacific Region
EQS-News: Lotus Pharmaceutical becomes strategic partner for the commercialization of Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® in the Asia-Pacific Region
eqs_en 
0 05.02.25
EQS-News: Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama®
EQS-News: Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama®
EQS-News: Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama®
eqs_en 
0 20.01.25
EQS-News: Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
EQS-News: Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
EQS-News: Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
eqs_en 
0 15.01.25
EQS-News: Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea®/ aflibercept) in major parts of Europe and Israel
EQS-News: Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea®/ aflibercept) in major parts of Europe and Israel
EQS-News: Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea®/ aflibercept) in major parts of Europe and Israel
eqs_en 
0 13.01.25
EQS-News: Formycon included in TecDAX Index of Deutsche Börse
EQS-News: Formycon included in TecDAX Index of Deutsche Börse
EQS-News: Formycon included in TecDAX Index of Deutsche Börse
eqs_en 
0 09.01.25
EQS-News: Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
EQS-News: Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
EQS-News: Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
eqs_en 
0 08.01.25